Aplastic Anaemia (AA)TTTNCT07131878
Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort
An observational study of Aplastic Anaemia (AA), run by Assiut University.
Trial summary
The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children Read more about this study
- Who is it for?
- Ages 1 year to 18 years
- Conditions the study is for
- Aplastic Anaemia (AA)
- How many people
- 35 participants
- Where
- No sites listed yet
- Study dates
- 15 Sep 2025to 15 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Children aged 1-18 years diagnosed with acquired aplastic anemia
Who may be able to join
- Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity <25% and at least two of the following: absolute neutrophil count <500/μL, platelet count <20,000/μL, absolute reticulocyte count <60,000/μL)123.
- The bone marrow biopsy should be compitable with diagnosis
- Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
- Patients with complete medical records, including diagnostic, laboratory, and treatment data
Who cannot join
- Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
- Patients with incomplete or missing essential data in their medical records.
- Patients diagnosed outside the specified study period or managed primarily at other institutions.
- Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
- Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children
Read the detailed description
This study will be conducted to investigate the clinical outcomes, and treatment modalities of patients diagnosed with aquired aplastic anaemia at Assiut University children Hospital
The main question it aims to answer is:
- Conditions
- Aplastic Anaemia (AA)
- Medical subject headings
- Anemia, Aplastic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| patient diagnosed with aplastic anemia from July 2023 to sept 2025 | Not described | |
| patient diagnosed with aplastic anemia from Sept 2025 to July 2026 | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the treatment outcomes of children diagnosed with aplastic anemia.
Measured: July 2023-July 2026
Secondary outcomes (1)
To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only
Measured: July 2023_July 2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2025
- Study start15 Sep 2025 (estimated)
- Primary completion15 Sep 2027 (estimated)
- Study completion15 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aplastic Anaemia (AA)Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Mohamed Abozaid, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07131878
- Sponsor's protocol ID
- Aquired Aplastic Anemia ttt
- Acronym
- TTT
- Status last verified
- Aug 2025
- First submitted
- 13 Aug 2025
- Last updated
- 20 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort
- ClinicalTrials.gov ID
- NCT07131878
- Acronym / sponsor ID
- TTT / Aquired Aplastic Anemia ttt
- Conditions
- Aplastic Anaemia (AA)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 15 Sep 2025 (estimated)
- Primary completion
- 15 Sep 2027 (estimated)
- Study completion
- 15 Jan 2028 (estimated)
- First posted
- 20 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children
Detailed description
This study will be conducted to investigate the clinical outcomes, and treatment modalities of patients diagnosed with aquired aplastic anaemia at Assiut University children Hospital
The main question it aims to answer is:
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patient diagnosed with aplastic anemia from July 2023 to sept 2025 | – | – |
| patient diagnosed with aplastic anemia from Sept 2025 to July 2026 | – | – |
Who may qualify
- Ages
- 1 year to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Children aged 1-18 years diagnosed with acquired aplastic anemia
Key inclusion criteria (4 listed)
- Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity <25% and at least two of the following: absolute neutrophil count <500/μL, platelet count <20,000/μL, absolute reticulocyte count <60,000/μL)123.
- The bone marrow biopsy should be compitable with diagnosis
- Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
- Patients with complete medical records, including diagnostic, laboratory, and treatment data
Key exclusion criteria (5 listed)
- Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
- Patients with incomplete or missing essential data in their medical records.
- Patients diagnosed outside the specified study period or managed primarily at other institutions.
- Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
- Patients exposed to antineoplastic chemotherapy or radiotherapy were excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To evaluate the treatment outcomes of children diagnosed with aplastic anemia.
Time frame: July 2023-July 2026
1 secondary outcome
To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only
Time frame: July 2023_July 2026
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Aplastic Anaemia (AA)
Not yet recruitingPhase 2
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
Aplastic Anaemia
Not yet recruitingPhase 2/3
A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment
Aplastic Anemia
RecruitingPhase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
Aplastic Anemia, de Novo Myelodysplastic Syndrome
RecruitingPhase 2
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Aplastic Anemia
Not yet recruiting
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
Aplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Aplastic Anaemia (AA), run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marwa M Abozaid, master (+201146679786, marwaabozaid39@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the treatment outcomes of children diagnosed with aplastic anemia. (time frame: July 2023-July 2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025.